Amyris Moving 30 Molecules Through R&D Pipeline, Streamlining Consumer Portfolio
Executive Summary
Amyris, Inc. is developing 30 molecules using its bio-fermentation technology, negotiating a bio-manufacturing joint venture that could yield $50m-$100m in proceeds, and simplifying its Consumer portfolio to unlock value. Cost containment and liquidity will continue to be key priorities for the synthetic biotech firm while it targets up to 100% revenue growth in fiscal 2023.
You may also be interested in...
Givaudan Strikes Deal For Amyris Ingredients, Long-Term Partnership
The deal has Amyris selling three key cosmetic ingredients to Givaudan and producing more biotech ingredients for the Swiss firm over the long term. “In the future, we will continue to push the boundaries of biotech, creating new sustainable innovations for a better beauty future,” says Givaudan’s Maurizio Volpi, president, Fragrance and Beauty.
Amyris Looks To Personal Care As Growth Engine For Renewable Ingredients
Sustainable ingredients being developed by Emeryville, Calif.-based biotech Amyris Inc. have piqued the interest of big players in the personal-care and fragrance industries.
Over The Counter 9 June 2023: Embracing AI/AR In Beauty, While Navigating Its Hurdles
In this episode of Over The Counter, HBW Insight speaks to Sampo Parkkinen, CEO and founder of Revieve, a firm that provides businesses with AI technology platforms to deliver a personalized brand experience. We discuss how artificial intelligence and augmented reality continue to shape beauty, where ChatGPT fits in and the importance of consumer privacy.